Structure of PF-05221304, a liver targeted inhibitor of acetyl-CoA carboxylase (ACC)

liver-targeted acetyl-CoA carboxylase inhibitor

oral hepatoselective activity obeserved in HV

from opt. of prior candidate for liver uptake

J. Med. Chem., Sep. 18, 2020

Pfizer, Cambridge, MA / Groton, CT

PF-05221304 is a liver targeted inhibitor of acetyl-CoA carboxylase (ACC). ACC is a key regulator of lipid metabolism, and there has been significant interest in ACC inhibitors for the treatment…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.